-
A New Hope for Hidradenitis Suppurativa: AbbVie’s Positive Phase 3 Lutikizumab Results
NYSE: $ABBV Breaking News in Dermatology AbbVie has recently shared promising topline results from their Phase 3 INTREPID trial, which evaluated the efficacy and safety of lutikizumab in patients living with moderate to severe hidradenitis suppurativa (HS). What the Trial Results Show The study marks a significant milestone for patients who have previously been treated…
-
New Treatment Milestone: FDA Approves Subcutaneous Induction Regimen for Skyrizi
NYSE: $ABBV A New Step Forward for Ulcerative Colitis Treatment The landscape of treatment for adults living with moderately to severely active ulcerative colitis (UC) has officially expanded. The FDA has approved a new subcutaneous induction regimen for AbbVie’s Skyrizi (risankizumab-rzaa), providing patients with a new, flexible option for managing their condition. What This Approval…
-
New Treatment Option: FDA Approves Subcutaneous Induction for Skyrizi in Crohn’s Disease
NYSE: $ABBV A New Milestone in Crohn’s Disease Management For adults living with moderately to severely active Crohn’s disease, there is a significant new development in treatment accessibility. The U.S. Food and Drug Administration (FDA) has officially approved a subcutaneous (SC) induction regimen for AbbVie’s Skyrizi (risankizumab-rzaa). What This Means for Patients Previously, patients often…
-
AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-?4?7 Monotherapy in Moderate to Severe Crohn’s Disease
NYSE: $ABBV NORTH CHICAGO, Ill., Oct. 19, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that its investigational ABBV-466, a novel dual-targeting therapy against IL-23 p19 and integrin α4β7, demonstrated higher rates of endoscopic… Source: Read More
-
A Major Milestone: AbbVie’s Telisotuzumab Vedotin Secures Two FDA Breakthrough Therapy Designations
NYSE: $ABBV Transforming Care for NSCLC Patients In a significant step forward for oncology, AbbVie has announced that the U.S. Food and Drug Administration (FDA) has granted two Breakthrough Therapy Designations (BTD) to their investigational therapy, telisotuzumab vedotin (Teliso-V). This recognition highlights the potential of this treatment to address the urgent needs of patients living…
-
A New Frontier in Weight Management: AbbVie’s ABBV-295 Shows Promise
NYSE: $ABBV The Quest for Next-Generation Obesity Treatments As the landscape of metabolic medicine continues to evolve, AbbVie has recently stepped into the spotlight with promising new data from its clinical development program. The company has officially shared detailed Phase 1 results for ABBV-295, an experimental, long-acting amylin analog designed to address the complex needs…
-
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline diagnosed diffuse large B-cell lymphoma (DLBCL) patients Based on the… Source: Read More
-
A New Chapter for Parkinson’s Care: FDA Approves Tavapadon (Juvmo)
NYSE: $ABBV A Significant Milestone in Parkinson’s Treatment The landscape of Parkinson’s disease management has officially expanded. The U.S. Food and Drug Administration (FDA) has granted approval for Juvmo (tavapadon), a new therapeutic option designed to support adults living with the motor symptoms associated with Parkinson’s disease. Understanding Tavapadon Tavapadon represents a novel approach in…